- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- Topic in appraisal
- Process:
- STA Standard
- ID number:
- 6325
Provisional Schedule
- Draft guidance:
- 23 July 2025 - 13 August 2025
- Expected publication:
- 05 November 2025
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- Gilead Sciences Ltd (brexucabtagene autoleucel)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Lymphoma Action
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Baxter Healthcare (cyclophosphamide, doxorubicin)- No CAU- Not participating
- BeiGene UK (zanubrutinib)- CAU signed- Participating
- Celltrion Healthcare UK (rituximab)- No CAU- Not participating
- Dr Reddy’s Laboratories UK (bendamustine)- No CAU- Not participating
- Hospira UK (cytarabine, vincristine)- No CAU- Not participating
- Jazz Pharmaceuticals UK (cytarabine)- No CAU- Not participating
- Medac GmbH (doxorubicin)- No CAU- Not participating
- Pfizer (rituximab, doxorubicin)- No CAU- Not participating
- Roche (rituximab)- No CAU- Not participating
- Sandoz (rituximab, cyclophosphamide)- No CAU- Not participating
- Seacross Pharmaceuticals (bendamustine, doxorubicin)- No CAU- Not participating
- Zentiva (bendamustine)- No CAU- Not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Cell and Gene Therapy Catapult
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 July 2025 | Declaration of interests |
| 01 July 2025 | Committee meeting: 1 |
| 06 December 2024 | Invitation to participate |
| 30 September 2024 - 28 October 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 16 May 2024 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual